Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 15:51 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Efficacy and Safety of Seralutinib in Adult Subjects With Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)
NCT07181382 · GB002, Inc. · PHASE3 · suspended · last registry update 2026-03-19 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Sponsor decision” | – | Registry record, GB002, Inc. |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against KIT within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2026-11-03Results posted on the registry: Jonsson Comprehensive Cancer Center, sorafenib tosylate (NCT01624285)
- 2026-10-29Results posted on the registry: Novartis Pharmaceuticals, imatinib mesylate (NCT01742299)
- 2026-10-21Results posted on the registry: The University of Texas Health Science Center at San Antonio, Sorafenib (SOR) + Hydroxychloroquine (HCQ) (NCT03037437)
- 2026-10-21Phase 3 first posted: Jiangsu Hansoh Pharmaceutical Co., Ltd., HS-10382 + Imatinib (NCT07885293)
- 2026-10-20Phase 3 first posted: Sun Yat-sen University, Benmelstobart + Anlotinib (NCT07881900)
- 2026-10-01Also stopped (withdrawn): City of Hope Medical Center, Sturlimogene Erparepvec + Tivozanib (NCT07218692)
- 2026-09-23Phase 3 first posted: BeOne Medicines, BGB-B2033 + Lenvatinib (NCT07836530)
- 2026-08-31Results posted on the registry: University of Texas Southwestern Medical Center, a drug against KIT (NCT02956798)
- 2026-08-25Also stopped (terminated): Association of Urologic Oncology (AUO), Sunitinib + Placebo (NCT01216371)
- 2026-07-20Phase 3 first posted: The Second Affiliated Hospital of Kunming Medical University, a drug against KIT (NCT07712848)
- 2026-07-14Results posted on the registry: Jennerex Biotherapeutics, JX-594 + Sorafenib (NCT01171651)
- 2026-07-09Results posted on the registry: Eli Lilly and Company, Pegilodecakin + Paclitaxel or Docetaxel and Carboplatin or Cisplatin (NCT02009449)
- 2026-07-08Results posted on the registry: Jennerex Biotherapeutics, JX-594 recombinant vaccina GM-CSF (NCT01387555)
- 2026-05-29Also stopped (terminated): Sarit Assouline, Asciminib + Imatinib (NCT05413915)
- 2026-05-20Also stopped (terminated): Massachusetts General Hospital, Tivozanib + Enzalutamide (NCT01885949)
- 2026-05-13Phase 3 first posted: GlaxoSmithKline, Velzatinib + Imatinib (NCT07585266)
- 2026-05-06Also stopped (suspended): AB Science, Placebo + Masitinib (4.5) (NCT05441488)
- 2026-04-24Results posted on the registry: Blueprint Medicines Corporation, Avapritinib (NCT03580655)
- 2026-04-15Phase 3 first posted: Second Affiliated Hospital, Zhejiang University, School of Medicine, Tofacitinib + Imatinib (NCT07530367)
- 2026-04-14Also stopped (terminated): Institut Claudius Regaud, Pazopanib (NCT01642017)
- 2026-04-08Results posted on the registry: National Cancer Institute (NCI), Olaparib + Pazopanib (NCT05432791)
- 2026-04-01Results posted on the registry: University of North Carolina, Chapel Hill, MCT + Clazakizumab (NCT04129931)
- 2026-03-30Results posted on the registry: HonorHealth Research Institute, Vemurafenib + Sorafenib (NCT05068752)
- 2026-03-25Results posted on the registry: University of Maryland, Baltimore, Imatinib + Placebo oral tablet (NCT04394416)
- 2026-03-25Also stopped (terminated): University of Maryland, Baltimore, Imatinib + Placebo oral tablet (NCT04394416)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision